Loading…
Employees: 987
Size Hubei Biocause Heilen Pharmaceutical (301211.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $682M, the 3124th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥10.89 on 6 Nov 2026.
Performance Over six months the shares fell 5.2%, against -6.1% for the median peer and -16.4% for the China market (cap-weighted) — 10th highest of 21 in its peer set.
Growth Revenue grew 13.5% over the last twelve months (peer median +17.7%); the operating margin is 4.1% (peer median 11.1%).
Valuation It trades at 6.2× enterprise value to sales against a peer median of 2.5× (5th most expensive of 17).
Capital Return on invested capital runs 5.3 points below its cost of capital (10.7% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥489M | CN¥451M | CN¥445M | CN¥659M | CN¥513M |
| Revenue growth | — | +1% | -33% | +29% | — |
| Gross profit | CN¥148M | CN¥90.9M | CN¥122M | CN¥257M | CN¥142M |
| EBITDA | n/a | CN¥47.5M | CN¥56.6M | CN¥167M | CN¥96.9M |
| Net income | CN¥53.6M | CN¥34.9M | CN¥91.5M | CN¥176M | CN¥126M |
| Free cash flow | -CN¥44.5M | -CN¥29.0M | -CN¥63.9M | -CN¥49.5M | CN¥175M |
| Capital expenditure | CN¥64.4M | CN¥52.3M | CN¥164M | CN¥187M | CN¥76.0M |
| Total debt | CN¥1.54M | CN¥14.4M | CN¥19.2M | CN¥24.8M | CN¥19.8M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 301211.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -12.0% | -4.9% | 8th lowest of 21 |
| 6-month return | -5.2% | -6.1% | 10th highest of 21 |
| Distance from 52-week high | -35.8% | -26.1% | 7th lowest of 21 |
| Revenue growth (TTM) | +13.5% | +17.7% | 8th lowest of 17 |
| Operating margin | 4.1% | 11.1% | 3rd lowest of 17 |
| EV / Sales | 6.2× | 2.5× | 5th most expensive of 17 |
| ROIC minus cost of capital | -5.3 pp | -1.7 pp | 5th lowest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hubei Biocause Heilen Pharmaceutical 301211.SZ | China | $682M | -5% | +13% | 4% | 6.2× | n/a | n/a |
| Earth 4985.T | Japan | $682M | +6% | +6% | 4% | 0.6× | -2.5% | -1.8% |
| Nuvectis Pharma NVCT | United States | $683M | +79% | n/a | n/a | n/a | n/a | n/a |
| Mochida Pharmaceutical 4534.T | Japan | $683M | -6% | +15% | 9% | 0.7× | n/a | n/a |
| Jenkem Technology 688356.SS | China | $686M | -23% | +52% | 11% | 10.9× | 41.4% | +11.2% |
| Hunan Fangsheng Pharmaceutical 603998.SS | China | $678M | -6% | +10% | 19% | 2.5× | -2.4% | +6.4% |
| Shandong Wit Dyne Health 000915.SZ | China | $687M | -33% | -36% | 36% | 2.5× | n/a | n/a |
| Center Laboratories 4123.TWO | Taiwan | $676M | -28% | +4% | 5% | 13.6× | 50.8% | +16.2% |
| Zevra Therapeutics ZVRA | United States | $690M | +4% | +75% | 31% | 3.4× | 0.0% | +51.6% |
| Achieve Life Sciences ACHV | United States | $692M | +29% | n/a | n/a | n/a | n/a | n/a |
| FDC FDC.NS | India | $672M | +4% | +10% | 14% | 2.5× | 25.9% | +10.3% |
| Beijing Beilu Pharmaceutical 300016.SZ | China | $692M | -16% | +23% | 11% | 3.2× | 10.3% | +7.9% |
| Sagimet Biosciences SGMT | United States | $693M | +28% | n/a | n/a | n/a | n/a | n/a |
| Philogen PHIL.MI | Italy | $694M | -7% | +295% | 79% | 0.9× | n/a | n/a |
| Immix Biopharma IMMX | United States | $668M | -17% | n/a | n/a | n/a | n/a | n/a |
| Bliss GVS Pharma BLISSGVS.NS | India | $698M | +126% | +21% | 15% | 6.6× | 37.0% | +10.1% |
| Zhejiang Wecome Pharmaceutical 300878.SZ | China | $666M | +10% | +40% | -65% | 19.0× | n/a | n/a |
| Sun Pharma Advanced Research SPARC.NS | India | $665M | +16% | +3,141% | 84% | 2.6× | n/a | n/a |
| Luoxin Pharmaceuticals Group Stock 002793.SZ | China | $664M | -26% | -10% | -9% | 2.2× | 0.3% | -17.9% |
| Lepu Biopharma 2157.HK | Hong Kong | $663M | -45% | +47% | 7% | 5.1× | n/a | n/a |
| Shandong Jincheng Pharmaceutical 300233.SZ | China | $661M | -25% | +2% | 4% | 1.4× | 1.1% | -1.6% |